MedTrace Logo

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

NCT01869725 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2021-09-22

Study results available
· View outcomes & findings →

Summary

This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging of patients with neuroendocrine tumors.

Conditions

  • Adult Medulloblastoma
  • Childhood Medulloblastoma
  • Neuroblastoma
  • Neuroendocrine Tumor
  • Somatostatinoma

Interventions

DRUG

gallium Ga 68-edotreotide

Given IV

PROCEDURE

positron emission tomography/computed tomography

Undergo gallium Ga 68-edotreotide PET/CT scan

RADIATION

indium In 111 pentetreotide

Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan

PROCEDURE

computed tomography

Undergo indium In 111 pentetreotide contrast-enhanced CT scan

PROCEDURE

contrast-enhanced magnetic resonance imaging

Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sue O'Dorisio

    lead OTHER

Principal Investigators

  • M. Sue O' Dorisio, MD, PhD · University of Iowa

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-01
Primary Completion
2018-12-26
Completion
2018-12-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01869725 on ClinicalTrials.gov